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Abstract In this paper we describe a novel 19 kDa sarcomeric 
protein named telethonin. The cDNA sequence discloses an open 
reading frame of 167 amino acids that does not resemble any 
known protein. Antibodies against a recombinant telethomn 
fragment were used for Western blot analysis, confirming the 
presence of this 19 kDa protein in heart and skeletal muscle and 
revealing an immunofluorescence pattern typical of sarcomeric 
proteins, overlapping myosin. The frequency of specific cDNA 
clones in different libraries indicates that the telethonin 
transcript is amongst the most abundant in skeletal muscle. In 
human, telethonin maps at 17ql2, adjacent to the phenyletha-
nolamine N-methyltransferase gene. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The systematic sequencing of expressed sequence tags 
(ESTs) is accelerating the discovery of new genes at an un-
precedented rate [1,22]. Comparison of the frequency of ESTs 
obtained from different tissues allows the inference of the 
pattern of gene expression [5,14] and in some cases may 
also be indicative of the relative abundance of the mRNAs 
[9,15]. 
We are currently engaged in a project for systematic se-
quencing of ESTs from human skeletal muscle [9]. The 
cDNA library used in this project was not subtracted or nor-
malised, thus allowing a reliable correlation between the fre-
quency of an EST and the relative abundance of the corre-
sponding mRNA in the muscle tissue. From this study many 
novel genes have been discovered, including some that appear 
to be expressed at a high level. 
In this paper we present a comprehensive study of a new 
gene expressed in human skeletal muscle, which we named 
telethonin since this work is entirely supported by Telethon, 
Italy. This gene corresponds to the most frequent EST that 
does not show any similarity to known genes, ranking 
amongst the 12 most abundant nuclear mRNAs transcribed 
in skeletal muscle. 
The sequence of telethonin has been submitted to the 
EMBL data library (accession number AJ000491) and is 
also accessible at our Web site http://eos.bio.unipd.it. 
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2. Materials and methods 
2.1. Cell culture and human tissue samples 
The following human lines were obtained from the American Type 
Culture Collection: Be Wo (choriocarcinoma), Detroit551 (skin, fibro-
blasts), HepG2 (hepatoma), IMR32 (neuroblastoma) and Tera-2 (ter-
atocarcinoma). The lines HL60 (human lymphoblasts) and K562 (er-
ythroleukaemia) were obtained from the Karolinska Institutet, 
Stockholm, Sweden. Samples of human skeletal muscle and heart 
were obtained from the Hospital of Padua. The RNA was extracted 
by the acid guanidium thiocyanate method [6]. 
2.2. Northern blot analysis 
The Northern blot analysis was performed on two filters supplied 
by Clontech. One filter was the 'Human muscle multiple tissue North-
ern blot' (cat. 7765-1) containing approximately 2 μg of poly A+ 
RNA per lane, from the following eight different human tissues: skel-
etal muscle, uterus (no endometrium), colon (no mucosa), small in-
testine, bladder, heart, stomach and prostate. The second filter was 
the 'Human multiple tissue Northern blot' (cat. 7760-1) containing 
approximately 2 μg of poly A+ RNA per lane, from the following 
eight different human tissues: heart, brain, placenta, lung, liver, skel-
etal muscle, kidney and pancreas. 
The hybridisation protocol and solutions were provided by Clon-
tech (ExpressHyb Hybridisation Solution, cat. S0910). The probe was 
obtained by random priming, using a PCR fragment obtained from 
the 3'-end untranslated region of the mRNA, using [32P]dATP. 
2.3. Construction and screening of a human skeletal muscle cDNA 
library by PCR 
A cDNA library suitable for the identification of full-length tran-
scripts was produced with a kit obtained from Invitrogen. The dou-
ble-stranded cDNA was ligated to BstXI-EcoRl adaptors (Invitrogen) 
and size-fractionated on an agarose gel in order to select fragments 
longer than 350 bp. The resulting preparation was inserted into the 
pCDNAII plasmid (Invitrogen) and used to transform the electro-
competent Escherichia coli strain TOPI OF'. 
A part of the library was aliquoted in 480 tubes, at a density of 50 
transformed bacteria per tube. Bacteria were grown to saturation and 
the plasmid DNA was extracted from each tube using the QIAwell 
system (Qiagen) and placed in five dishes of 96 wells, corresponding to 
480 pools of DNA, each consisting of the plasmids from about 50 
different bacterial clones. 
The screening of the cDNA library was carried out on the pools of 
plasmids described above and based on PCR. Firstly, the 480 pools 
were processed by PCR using two telethonin-specific primers. The 
pools that produced a band of the expected size were considered to 
contain at least one telethonin cDNA and were further analysed by 
means of two parallel PCRs: one with the T15-REV and the Univer-
sal-FOR primer, the other with the T15-REV and the Universal-REV 
primer. The two 'Universal' primers corresponded to two sequences of 
the plasmid, located on opposite sides of the cloning site. Depending 
on whether an amplified band was produced with the Universal-FOR 
or the Universal-REV primer, it was possible to deduce the orienta-
tion of the insert. The agarose gel analysis also allowed the identifi-
cation of the longest cDNA inserts that could be selected for further 
processing and sequencing. 
DNA sequencing was carried out directly on 5 μΐ of the PCR re-
actions using either the Dye-deoxy-terminator chemistry or the Dye-
primer chemistry (Applied Biosystems) and run on an ABI377 DNA 
sequencer (Applied Biosystems). 
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2.4. Immunochemistry and immunofluorescence 
A cDNA fragment of telethonin with appropriate restriction en-
zyme sites was obtained by RT-PCR and inserted into the prokaryote 
expression vector pQE9 (Qiagen). Telethonin in pQE9 was sequenced 
to confirm that there were no major changes from the original tran-
script. The recombinant protein was expressed in E. coli after induc-
tion by IPTG and was purified by affinity chromatography on Ni-
NTA (nickel-nitrilotriacetic acid) resin. The eluted protein was dia-
lysed against Tris-buffered saline (TBS) pH 8 to remove the 8 M urea. 
The recombinant telethonin was used to immunise three mice for the 
production of polyclonal antibodies. Mice were injected six times, at 
intervals of approximately 10 days. 
Polyadenylated mRNA from human skeletal muscle was translated 
in vitro using the Promega wheat germ translation system and 
[35S]methionine. Equal amounts of labelled skeletal muscle proteins 
were mixed with 2 μΐ of appropriate antibody (anti-telethonin or pre-
immune mouse serum) and then immunoprecipitated with protein A 
Sepharose CL-4B beads (Pharmacia) in a buffer containing 50 mM 
HEPES pH 8.0, 250 mM NaCl, 0.1% NP40. The resulting immuno-
precipitated samples were run on 15% SDS-polyacrylamide gels and 
autoradiographed. 
For Western blotting, fragments of frozen heart muscle were homo-
genised under liquid nitrogen using a mortar and pestle. The resulting 
powder was resuspended in SDS-PAGE sample buffer, boiled and run 
on a preparative 15% SDS-acrylamide gel (approximately 20 μg of 
total protein per lane). The polyclonal antibody to telethonin was 
used at a 1:200 dilution. A goat anti-mouse alkaline phosphatase 
was used as a second antibody (Sigma A3562). 
For immunofluorescence, frozen sections about 6 μpiι thick were 
prepared from human skeletal muscle (Vastus) using a Leica Jung/ 
CM/1800 cryostat. As first antibodies we used the mouse anti-tele-
thonin serum diluted 50 times and/or a rabbit anti-skeletal myosin 
antibody (Sigma M7523). As a second antibody we used a TRITC-
labelled goat anti-mouse immunoglobulin (Sigma T7657) and/or a 
FITC-labelled goat anti-rabbit immunoglobulin (Sigma F0511). 
FITC-phalloidin (Sigma P5282) was used as a specific ligand of actin. 
All the commercial immunochemicals were diluted as recommended 
by the suppliers. 
2.5. Genomic mapping 
The genomic mapping was performed by PCR, with the radiation 
hybrids method, using the GeneBridge 4 whole-Genome Radiation 
Hybrid Panel (Research Genetics) consisting of 93 genomic DNA 
preparations from human-on-hamster somatic cell lines [26]. The 
screening results were processed with the RHMAPPER software pro-
gram, available from the Whitehead Institute/MIT Center for Ge-
nomic Research (Cambridge, MA, USA). 
3. Results 
3.1. Molecular cloning and characterisation of the telethonin 
mRNA 
From the systematic sequencing of human skeletal muscle 
ESTs carried out in our laboratory [9], many novel genes have 
been discovered, including some that appear to be expressed 
at a high level. Currently, more than 10000 ESTs have been 
identified, representing well over 1500 different independent 
transcripts. The current list of the most frequent nuclear tran-
scripts is given in Table 1 where the relative frequencies are 
also shown. It can be seen that telethonin is amongst the most 
abundant transcripts, ranking at the 12th position. 
The cDNA libraries used for EST sequencing were espe-
cially designed to contain only the 3'-end of the transcripts 
[9]. Although this confers several advantages to the overall 
project, it makes the recovery of a full-length sequence more 
difficult. To overcome this problem we have produced a sep-
arate 'full-length' cDNA library and set up a fast screening 
method based on PCR, as described in Section 2. From the 
PCR screening of about 24000 transformant plasmids we 
found 105 positives. The sequence shown in Fig. 1 was pro-
duced from some selected cDNA inserts. 
The total length of the nucleotide sequence shown in Fig. 1 
is 959 bases. The translation of the sequence reveals an open 
reading frame of 501 bases, encoding a putative protein of 167 
amino acids with a molecular weight of 19051 Da. 
Both nucleotide and amino acid sequences were used to 
perform extensive similarity searches in the EMBL nucleic 
acid database and in the SwissProt protein database using 
several programs such as FASTA [17], BlastN, BlastX [2], 
MPSearch [24] and BioSCAN [23]; however, these searches 
did not reveal significant similarity to any known gene. 
Genomic mapping was performed with the radiation hy-
brids technique, as described in Section 2, revealing that the 
telethonin gene maps on the human genome on chromosome 
17ql2, with a very significant lod score ( > 15). Further evi-
dence of the chromosomal position of the telethonin gene 
comes from the finding that the very last 50 bases found at 
the 3'-end of the transcript overlap the beginning of a ge-
nomic fragment that includes the human phenylethanolamine 
/V-methyltransferase gene which is also known to map to 
chromosome 17 [8]. The distance between the end of the tele-
thonin transcript and the beginning of the phenylethanol-
amine /V-methyltransferase gene is approximately 1900 bases. 
3.2. Northern blot analysis 
The tissue specificity of the telethonin transcript was studied 
in several tissues by Northern blot analysis and the results are 
reported in Fig. 2. The expression of telethonin seems to be 
restricted to skeletal and heart muscle as under normal expo-
sure conditions it cannot be detected in any other tissues in-
cluding those containing smooth muscle such as stomach, 
bladder, intestine, colon, uterus and prostate. However, after 
Table 1 
List of the 24 most abundant nuclear transcripts from our human 
skeletal muscle EST work [9,16] 
Transcript Frequency/ 
10000 ESTs 
1 Skeletal alpha-actin 
2 Alpha globin 
3 Skeletal muscle myosin light chain 2 
4 Slow skeletal muscle troponin T 
5 Creatine kinase 
6 Glyceraldehyde-3-P dehydrogenase 
7 Ribosomal protein L37a 
8 Troponin I, slow-twitch isoform 
9 Myoglobin 
10 Fast skeletal muscle myosin H-chain 
11 Skeletal muscle beta-tropomyosin 
12 Telethonin 
13 Ribosomal protein L41 
14 Fast skeletal muscle troponin C 
15 Fast skeletal muscle myosin L-chain 2 
16 Skeletal muscle myosin alkali L-chain 
17 Fructose 1,6-diphosphate aldolase A 
18 Beta-globin 
19 EST (skeletal muscle cDNA library) 
20 Desmin 
21 Cytochrome c oxidase subunit Vila 
22 Skeletal muscle troponin I fast-twitch 
23 Fast 2a skeletal muscle myosin H-chain 
24 Ribosomal protein Sl l 
830 
256 
208 
199 
181 
92 
76 
64 
61 
60 
55 
51 
51 
47 
45 
42 
41 
40 
39 
39 
38 
36 
36 
32 
The frequency is calculated as the number of times that a transcript 
was found in 10000 ESTs, counting also the mitochondrial transcripts 
(not shown in this list). 
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CGGCACGAGCATGGCTACCTCAGAGCTGAGCTGCGAGGTGTCGGAGGAGAACTGTGAG 58 
R R E A F W A E W K D L T L S T R P E 35 
CGC CGG GAG GCC TTC TGG GCA GAA TGG AAG GAT CTG ACA CTG TCC ACA CGG CCC GAG 115 
E G C S L H E E D T Q R H E T Y H Q Q 54 
GAG GGC TGC TCC CTG CAT GAG GAG GAC ACC CAG AGA CAT GAG ACC TAC CAC CAG CAG 172 
G Q C Q V L V Q R S P W L M M R M G I 73 
GGGCAGTGCCAGGTGCTGGTGCAGCGCTCGCCCTGGCTGATGATGCGGATGGGCATC 229 
L G R G L Q E Y Q L P Y Q R V L P L P 92 
CTC GGC CGT GGG CTG CAG GAG TAC CAG CTG CCC TAC CAG CGG GTA CTG CCG CTG CCC 286 
I F T P A K M G A T K E E R E D T P I 111 
ATC TTC ACC CCT GCC AAG ATG GGC GCC ACC AAG GAG GAG CGT GAG GAC ACC CCC ATC 343 
Q L Q E L L A Z E T A L G G Q C V D R 130 
CAG CTT CAG GAG CTG CTG GCG CTG GAG ACA GCC CTG GGT GGC CAG TGTGTG GAC CGC 400 
Q E V A E I T K Q L P P V V P V S K P 149 
CAG GAG GTG GCT GAG ATC ACA AAG CAG CTG CCC CCT GTG GTG CCT GTC AGC AAG CCC 457 
G A L R R S L S R S M S Q E A Q R G - 167 
GGT GCA CTT CGT CGC TCC CTG TCC CGC TCC ATG TCC CAG GAA GCA CAG AGA GGC TGA 514 
GAGGGACTGTGACTTGGGCTCCGCTGTGCCCGCCCTGGGC^ 580 
AGGGGAGCTGCTGGCCATGGCTGCTTTGTAGTTTGCCC^^ 646 
CÄGAGGCCÄGGATGCCTGAGCCCCCTGAGTTCCCÄAAGG^ 712 
GGGTGGAGAGTTGGGGGCCaGOVCAGCTGAGGaCCCTO^ 778 
GGTGAGGGCAAGAGGTGCCTGGGAGGÄGTGGCCCTGATCCAGGAAAAIGT^ 844 
GCTCTAGGOW3AAGAAGCTGGGAGGGAGGGGGAGGTGAAAAGGGCAGAGGCAAGGATGGTGGGGCC 910 
CCCAGC^^CCTCTGTTAGTGCCGCAATAAAlXKTCAATCATGTGCCAGA-poly(A) 959 
Fig. 1. Nucleic acid sequence of the telethonin transcript. The translated amino acid sequence is shown in italics above each codon. The TGA 
stop codon is represented by a dash. 
a prolonged exposure of the filter, a very faint band was 
observed in the prostate lane (data not shown). 
Further evidence that telethonin exhibits a very restricted 
pattern of expression came from RT-PCR [19] and RNase 
protection assay [27], performed on skeletal muscle, heart 
and a variety of cell lines (see Section 2). Also in these cases 
the telethonin transcript was only detected in skeletal muscle 
and heart (data not shown). 
3.3. Antibodies, immunoprecipitation and Western blot analysis 
A recombinant fragment of telethonin consisting of 128 C-
terminus amino acids (SLHEE...EAQR) was produced in E. 
coli and used for the immunisation of three mice as described 
in Section 2. 
The anti-telethonin antibodies were used for immunoprecip-
itation and Western blot analysis (Fig. 3) revealing a band of 
about 19-20 kDa. From the immunoprecipitation results (Fig. 
3, left) it can be seen that the anti-telethonin antibodies bring 
down a single band. There are no other visible bands co-pre-
cipitating with telethonin under the experimental conditions 
used. 
The Western blot analysis (Fig. 3, right) was repeated in-
dependently with sera from three different mice, producing a 
single band of the expected size, whereas the serum from a 
pre-immune mouse did not produce any detectable band. Im-
mune sera produced in a similar way against other recombi-
nant proteins obtained from pQE9 revealed different bands 
from those of Fig. 3 (data not shown). In conclusion, we 
can say that the antibodies raised against the putative tele-
thonin protein displayed in Fig. 1 do actually recognise a 
band of the expected size; therefore, the sequence presented 
in Fig. 1 most likely covers the entire coding sequence of 
telethonin. 
Further evidence that the sequence presented in Fig. 1 cov-
ers the full coding region of telethonin is given in Fig. 4, 
where the natural form of telethonin found in skeletal muscle 
and heart is compared with the recombinant form produced in 
bacteria, using Western blot analysis. It can be seen that the 
recombinant form of telethonin runs slightly more slowly as a 
result of the histidine tag used for affinity purification (see 
Section 2). 
The intensity of the Western blot signal (Fig. 4) can be used 
as an indication of the relative amount of telethonin in skel-
etal muscle and heart, based on the comparison with known 
amounts of recombinant telethonin. The densitometric analy-
sis of the bands (not shown) gives a perfect correlation with 
the amount of control telethonin loaded on the gel and indi-
cates a relative amount of 5 ng of telethonin per 10 μg of total 
muscle protein, in both heart and skeletal muscle. 
3.4. Immunofluorescence 
To elucidate the intracellular localisation of telethonin we 
Fig. 2. Northern blot analysis of several human tissues using the 3' 
untranslated region of telethonin as a probe. 
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Fig. 3. Immunoprecipitation and Western blot analysis of teletho-
nin. The immunoprecipitation (left) was carried out as described in 
Section 2, from a wheat germ in vitro transcription system, using 
polyadenylated RNA from skeletal muscle. The non-immunoprecipi-
tated sample was obtained from 2 μΐ of reaction, whereas the two 
immunoprecipitated samples were obtained from 15 μΐ after incuba-
tion either with mouse pre-immune serum or with a serum from a 
mouse immunised with the recombinant telethonin. It can be seen 
that pre-immune serum does not precipitate any band, whereas the 
anti-telethonin brings down a single band of approximately 19-20 
kDa. The Western blot analysis is shown on the right. A fragment 
of human heart muscle was homogenised and run on a 15% SDS-
PAGE, as described in Section 2. After blotting, four identical ni-
trocellulose strips were cut and probed with four different mouse 
antisera diluted 200 times. Strip 1: pre-immune serum; strips 2, 3 
and 4: polyclonal antibodies from three different mice immunised 
with the recombinant telethonin. The positions of the molecular 
weight markers (kDa) are indicated at the side of the figure. 
performed some immunofluorescence analyses on skeletal 
muscle. An indirect immunofluorescence assay revealed a 
banding typical of sarcomeric proteins, visible as rhodamine 
red fluorescence in Fig. 5a,d. To establish the relationship 
between the banding of telethonin and that of other major 
sarcomeric proteins such as myosin and actin, we performed 
double immunofluorescence assays, where myosin and actin 
were revealed by fluorescein green staining, as described in 
Section 2. The results are presented in Fig. 5b,e, where the 
actin and myosin patterns are shown in the same sections as 
in Fig. 5a,d. From the overlapping of the two images it can be 
seen that the banded pattern displayed by telethonin overlaps 
that of myosin (Fig. 5f) and alternates with actin (Fig. 5c). 
Frames g, h and i of Fig. 5 show several negative controls that 
support the double immunofluorescence data and confirm that 
the pattern observed is not due to artefacts that sometimes 
occur in double immunofluorescence staining. 
4. Discussion 
The main point from the work presented in this paper is 
that a new major sarcomeric protein has been discovered. 
Therefore, the understanding of how this new protein relates 
to other known sequences is of primary interest. As was an-
ticipated in Section 3, the sequence similarity searches did not 
reveal any significant similarity to any known gene or protein. 
The amino acid sequence was also analysed for the presence 
of known amino acid domains and motifs, against respectively 
the Sbase [18] and the Prosite [4] databases. The only find-
ing from the Prosite search is the presence of several pu-
tative phosphorylation sites, whereas a similarity search 
against Sbase uncovered a weak correlation with 25 amino 
acids from the catalytic domain of the KIR serine/threonine 
protein kinase receptors, with 48% identity. Although the 
possible involvement of kinase activities is very fascinating, 
it is far from being proven and these data should only be 
taken as the best matches found by the above computer 
searches. 
The Psort program [13] indicated that telethonin is a prob-
able cytoplasmic protein and the Predict program [21] showed 
that it does not contain any transmembrane domain, thus 
confirming the hypothesis of a sarcomeric protein, as indi-
cated by the immunofluorescence data. 
4.1. Relative abundance of the transcript and pattern of 
expression 
The second major question that arises from this work is 
whether the telethonin transcript is really as abundant as it 
appears from our EST work, ranging around 0.51% of the 
polyadenylated mRNA molecules. The method that has 
been developed in our laboratory for the construction of the 
cDNA libraries used for EST sequencing gives a good corre-
spondence between the relative amount of the mRNAs and 
the number of cDNA inserts found in the library [9]. Further-
more, very similar results were found from two independent 
libraries produced in our laboratory and used for EST se-
quencing. The first library was obtained from a pectoral 
muscle of a woman after mastectomy, the second from a 
gastrocnemium of a man after leg amputation. 
Further evidence of the high level of telethonin mRNA 
comes from the frequency of the positive clones in the full-
length cDNA library. As described in Section 2, the library 
was screened by PCR. A total of 24000 cDNA clones were 
probed in 480 groups of 50, giving 105 positives. Although 
105/24000 makes 0.44%, it must be calculated that the screen-
ing was done in groups of 50 and that some groups may 
μ^ of total muscle protein 
ng of purified telethonin Skeletal Hc¡r tT 
7.50 3.75 1.87 0.93 0.43 "~5 U P 1 10 
Fig. 4. Western blot analysis of known amounts of full-length re-
combinant telethonin produced and purified from bacteria (on the 
left) and known amounts of total protein from human heart and 
skeletal muscle (right). The slightly larger size of the recombinant 
protein is due to the N-terminal histidine tag used for affinity purifi-
cation (see Section 2). The recombinant telethonin was purified by 
electro-elution from a preparative polyacrylamide gel; then it was 
quantified by a Bio-Rad protein assay and finally loaded on the gel 
for Western blot analysis. The anti-telethonin antibodies were ob-
tained from a portion of telethonin that was lacking about 20 ami-
no acids at the N-terminus. From a densitometric analysis of the 
bands it can be calculated that the telethonin signal from 10 μg of 
total muscle proteins (from heart or skeletal muscle) is approxi-
mately equivalent to 5 ng of purified telethonin. 
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Fig. 5. Immunofluorescence analysis of skeletal muscle to detect telethonin (red), actin (green, left) and myosin (green, centre). The three frames 
on the left (a, b, c) show the same field of a section of human skeletal muscle where rhodamine (red) corresponds to telethonin while fluores-
cein (green) corresponds to actin. Frame a shows the rhodamine channel, frame b shows the fluorescein channel and frame c shows the two 
superimposed channels. Similarly, frames d, e and f show another section of skeletal muscle where rhodamine corresponds to telethonin while 
fluorescein corresponds to myosin. It can be seen that the red fluorescence (telethonin) coincides with the green myosin banded pattern (frame 
f), whereas it displays an alternate green/red banded pattern when compared with actin (frame c). The three frames on the right display the 
negative controls, g: Pre-immune mouse serum, h: Section incubated with mouse anti-telethonin as a first antibody, followed by goat anti-rab-
bit IgG as a second antibody, to show that the anti-rabbit IgG does not cross-react with the mouse IgG. i: Section incubated with rabbit anti-
myosin as a first antibody, followed by goat anti-mouse IgG as a second antibody, to show that the anti-mouse IgG does not cross-react with 
the rabbit IgG. Further details of the double immunofluorescence protocol are described in Section 2. 
contain multiple positives, bringing the corrected value to 
about 0.52%: a very similar figure to that found by sequenc-
ing the EST libraries. 
Although the telethonin sequence did not show any simi-
larity to known genes, it matches several ESTs identified in 
other laboratories. Fourteen such matches were found in Re-
lease 49 of the EMBL-EST library. In these cases the frequen-
cies of the ESTs cannot be taken as an indication of the 
relative abundance of the transcript because these cDNA li-
braries were subtracted or normalised. However, the fact that 
13 out of 14 ESTs are from skeletal muscle [3] or heart [11,25] 
is further evidence of the pattern of expression restricted to 
muscle. 
At the protein level telethonin appears to be also present at 
a high amount, although not quite as high as at the RNA 
level. The 5 ng of telethonin per 10 μg of total muscle protein 
(Fig. 4) gives a figure of 0.05% which may seem low when 
compared with the 0.5% found at the RNA level. However, 
the RNA was measured as relative number of molecules 
whereas the protein was measured as relative mass. This is 
particularly relevant since the molecular weight of telethonin 
is only 19 kDa which is much smaller than the average pro-
tein. It is also plausible that telethonin is not as stable as most 
muscle proteins. This possibility is substantiated by the anal-
ysis of the Instability Index [7], which gives a value of 69.35, 
when values above 40 are indicative of a possible instability of 
the protein. 
4.2. Genomic mapping and possible link to genetic diseases 
The radiation hybrids assay allowed us to position the tele-
thonin gene on the human chromosome 17ql2. Several genetic 
disorders map to this region, including some responsible for 
myopathies such as malignant hyperthermia susceptibility-2 
[10] and adhalinopathy [12,20]. The finding that telethonin 
maps to 17ql2 opens interesting new possibilities of investi-
gation on the molecular characterisation of these diseases. 
Acknowledgements: We are grateful to Professor G.A. Danieli, Uni-
versity of Padua, for advice in the course of the investigation and for 
constant encouragement. We also thank F. Caldara and A. Albarelli 
for assistance with computer analysis, and B. Simionati, V. Favino 
and R. Zimbello for their contribution to the sequencing work and to 
genome mapping. We also wish to thank Dr. V. Tegazzin, Padua City 
Hospital, for the specimen of gastrocnemium and Professor S. Schiaf-
fino, University of Padua, for the specimen of vastus. This work was 
supported by Telethon Italy (Grants B30 and B39). 
References 
[1] Adams, M.D., Kelley, J.M., Gocayne, J.D., Dubnick, M., Poly-
meropoulos, M.H., Xiao, H., Merril, C.R., Wu, A., Olde, B., 
Moreno, R., Kerlavage, A.R., McCombie, W.R. and Venter, J.C. 
(1991) Science 252, 1651-1656. 
[2] Altschul, S.F., Gish, W., Miller, W., Myers, E.W. and Lipman, 
D J . (1990) J. Mol. Biol. 215, 403^410. 
[3] Auffray, C , Behar, G., Bois, F., Bouchier, C , da Silva, C , De-
vignes, M.D., Duprat, S., Houlgatte, R., Jumeau, M.N., Lamy, 
B., Lorenzo, F., Mitchell, H., Mariage-Samson, R., Pietu, G., 
Pouliot, Y., Sebastiani-Kabaktchie, C. and Tessier, A. (1995) 
C.R. Acad. Sei. Ill Sei. Vie 318, 263-272. 
[4] Bairoch, A. (1993) Nucleic Acids Res. 21, 3097-3103. 
[5] Boguski, M.S. and Schuler, G.D. (1995) Nature Genet. 10, 369-
371. 
[6] Chomczynski, P. and Sacchi, N. (1987) Anal. Biochem. 162, 156-
159. 
[7] Guruprasad, K., Reddy, B.V.B. and Pandit, M.W. (1990) Protein 
Eng. 4, 155-161. 
[8] Kaneda, N., Ichinose, H., Kobayashi, K., Oka, K., Kishi, F., 
Nakazawa, A., Kurosawa, Y., Fujita, K. and Nagatsu, T. 
(1988) J. Biol. Chem. 263, 7672-7677. 
[9] Lanfranchi, G., Muraro, T., Caldara, F., Pacchioni, B., Pallavi-
cini, A., Pandolfo, D., Toppo, S., Trevisan, S., Scarso, S. and 
Valle, G. (1996) Genome Res. 6, 35^12. 
[10] Levitt, R.C., Olckers, A., Meyers, S., Fletcher, J.F., Rosenberg, 
H., Isaacs, H. and Meyers, D.A. (1992) Genomics 14, 562-566. 
[11] Liew, C.C., Hwang, D.M., Fung, Y.W., Laurenssen, C , Cuker-
man, E., Tsui, S. and Lee, C.Y. (1994) Proc. Nati. Acad. Sei. 
USA 91, 10645-10649. 
[12] McNally, E.M., Yoshida, M., Mizuno, Y., Ozawa, E. and Kun-
kel, L.M. (1994) Proc. Nati. Acad. Sei. USA 91, 9690-9694. 
G. Valle et al.lFEBS Letters 415 (1997) 163-168 
[13] Nakai, K. and Kanehisa, M. (1992) Genomics 14, 897-911. 
[14] Okubo, K., Itoh, K., Fukushima, A., Yoshii, J. and Matsubara, 
K. (1995) Genomics 30, 178-186. 
[15] Okubo, K., Hori, N., Matoba, R., Niiyama, T., Fukushima, A., 
Kojima, Y. and Matsubara, K. (1992) Nature Genet. 2, 173-179. 
[16] Pacchioni, B., Trevisan, S., Gomirato, S., Toppo, S., Valle, G. 
and Lanfranchi, G. (1996) BioTechniques 21, 644-649. 
[17] Pearson, W.R. and Lipman, D J . (1988) Proc. Nati. Acad. Sei. 
USA 85, 2444-2448. 
[18] Pongor, S., Hatsagi, Z., Degtyarenko, K., Fabian, P., Skerl, V., 
Hegyi, H., Murvai, J. and Bevilacqua, V. (1994) Nucleic Acids 
Res. 22, 3610-3615. 
[19] Rappolee, D.A., Wang, A., Mark, D. and Werb, Z. (1989) J. Cell 
Biochem. 39, 1-11. 
[20] Roberds, S.L., Anderson, R.D., Ibraghimov-Beskrovnaya, O. 
and Campbell, K.P. (1993) J. Biol. Chem. 268, 23739-23742. 
[21] Rost, B., Sander, C. and Schneider, R. (1994) CABIOS 10, 53-
60. 
[22] Sikela, J.M. and Auffray, C. (1993) Nature Genet. 3, 189-191. 
[23] Singh, R.K., Hoffman, D.L., Tell, S.G. and White, C.T. (1996) 
CABIOS 12, 191-196. 
[24] Sturrock, S.S. and Collins, J.F. (1993) MPsrch version 1.3. Bio-
computing Research Unit, University of Edinburgh, Edinburgh. 
[25] Tanaka, T., Ogiwara, A., Uchiyama, I., Takagi, T., Yazaki, Y. 
and Nakamura, Y. (1996) Genomics 35, 231-235. 
[26] Walter, M.A., Spillet, DJ . , Thomas, P., Weissenbach, J. and 
Goodfellow, P.N. (1994) Nature Genet. 7, 22-28. 
[27] Zinn, K., Di Maio, D. and Maniatis, T. (1983) Cell 34, 865-
879. 
